I'm working on the Wnt/beta-signalling pathway.
We observed something interesting and woud apprecuate if someone could shed some light on this. Treatment of our drug increaes total beta-catenin protein levels but it decreases its target genes (cmyc and DKK1). I find this puzzling. I thought an increase in beta catenin would increase expression of downstream target genes.
Perhaps another factor in the nucleus is preventing binding of beta-catenin/TCF to wnt target gene? I cannt think of another explanation.